[Skip to Navigation]
Sign In
Correction
August 12, 2021

Errors in Abstract and Results

JAMA Oncol. 2021;7(9):1405-1406. doi:10.1001/jamaoncol.2021.4021

In the Original Investigation titled “Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial,”1 published online June 24, 2021, there were discrepancies between the published data and updated analysis with regard to the evaluation of fluorine 18–labeled fluorodeoxyglucose positron emission tomography combined with computed tomography.

In the Abstract, the sentence given with “a relative decrease of maximum standardized uptake value by more than 31.3% (median) was associated with pCR (odds ratio, 6.67, 95% CI, 2.38-20.00; P < .001)” has been updated to “a relative decrease of maximum standardized uptake value equal or greater than 68.7% (median) was associated with pCR (odds ratio, 6.74; 95% CI, 2.75-16.51; P < .001).”

In the Results, the following sentence appeared: “Using the median decrease by the relative change of the maximum standardized uptake value from baseline to cycle 2 of 31.3% as a cutoff, a decrease of the maximum standardized uptake value by more than 31.3% was associated with pCR in 79.6% of patients (43 of 54) compared with 42.6% of patients (23 of 54) with a relative change of the maximum standardized uptake value from baseline to cycle 2 of 31.3% or less, irrespective of treatment group (OR, 6.67; 95% CI, 2.38-20.00; P < .001).”

This sentence has been corrected to read: “Using the median decrease by the relative change of the maximum standardized uptake value from baseline to cycle 2 of 68.7% as a cutoff, a decrease of the maximum standardized uptake value equal or greater than 68.7% was associated with pCR in 57.4% of patients (31 of 54) compared with 16.7% of patients (9 of 54) with a decrease less than 68.7% (OR, 6.74; 95% CI, 2.75-16.51; P < .001).”

This article has been corrected online.

References
1.
Hatschek  T, Foukakis  T, Bjöhle  J,  et al.  Neoadjuvant trastuzumab, pertuzumab, and docetaxel vs trastuzumab emtansine in patients with ERBB2-positive breast cancer: a phase 2 randomized clinical trial.   JAMA Oncol. Published online June 24, 2021. doi:10.1001/jamaoncol.2021.1932PubMedGoogle Scholar
×